Clinical trial
Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of…
NCT00354887 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00354887 |
|---|---|
| Title | Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater |
| Official title | A Phase II Study of Capecitabine and Oxaliplatin (XELOX) in Adenocarcinoma of the Small Bowel and Ampulla of Vater |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Sanofi-Synthelabo Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastrointestinal Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine, Oxaliplatin |
| Enrollment | 31 |
| Start date | Nov 1, 2004 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Jul 20, 2006 |
| Last update posted | Oct 29, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: